[1]董正川,段玉清,樊赛军,等.新型辐射增敏药RRx-001[J].国际放射医学核医学杂志,2017,41(3):214-219.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
　Dong Zhengchuan,Duan YuQing,Fan Saijun,et al.A novel radiosensitizer RRx-001[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):214-219.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
点击复制

新型辐射增敏药RRx-001(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第3期
页码:
214-219
栏目:
综述
出版日期:
2017-05-25

文章信息/Info

Title:
A novel radiosensitizer RRx-001
作者:
董正川1;  段玉清2;  樊赛军2;  李祎亮2
1. 300193, 天津中医药大学研究生院;
2. 300192 天津, 中国医学科学院 北京协和医学院 放射医学研究所, 天津市放射医学与分子核医学重点实验室
Author(s):
Dong Zhengchuan1;  Duan YuQing2;  Fan Saijun2;  Li Yiliang2
1. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;
2. Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peki
关键词:
辐射增敏药; 一氧化氮; RRx-001
Keywords:
Radiation-sensitizing agents; Nitric oxide; RRx-001
DOI:
10.3760/cma.j.issn.1673-4114.2017.03.011
摘要:
辐射增敏药可提高射线对肿瘤细胞，尤其是乏氧细胞的杀伤率，增强放疗效果，且其对有氧正常组织危害小，使用方便，因而有望成为放疗中的重要辅助药物。新型二硝基氮杂环丁烷辐射增敏药RRx-001源自航空产业。作为一氧化氮的供体分子，RRx-001可透过红细胞膜，与血红蛋白的β半胱氨酸93结合，并在乏氧环境中大量释放一氧化氮，从而提高乏氧细胞对照射的敏感度。临床实验显示RRx-001具有良好的安全性和耐受性。目前其对胆管癌、结直肠癌等肿瘤的治疗正在进行临床Ⅱ期实验。
Abstract:
The effect of radiotherapy can be enhanced by radiosensitizers because these compounds can improve the killing rate of radiation on tumor cells, especially on hypoxic cells. Moreover, radiosensitizers show little damage to the aerobic normal tissue and are easy to use. For these reasons, radiosensitizers are expected to become the important treatment in radiotherapy. RRx-001, a novel dinitroazetidine radiosensitizer, is an aerospace industry-derived anti-cancer agent. As an NO-donating compound, RRx-001 can pass through erythrocyte membrane, selectively bind to hemoglobin at the beta-cysteine 93 residue, and release large amounts of NO under hypoxic conditions, so as to improve radiosensitivity of hypoxic cells. RRx-001 shows good safety and tolerability in clinical studies and now is undergoing phase Ⅱ clinical trials in cholangiocarcinoma, colorectal neoplasms, ect.

参考文献/References:

[1] 冉晨曦, 何人可, 汤小玲, 等. 肿瘤放射治疗中辐射增敏剂的应用进展[J]. 山东医药, 2015,55(3):86-88. Ran CX, He RK, Tang XL, et al. Application progress of radiosensitizer in tumor radiotherapy[J]. Shangdong Med J, 2015, 55(3):86-88.
[2] Tubiana M. The role of local treatment in the cure of cancer[J]. Eur J Cancer, 1992, 28A(12):2061-2069. DOI:10.1016/0959-8049(92)90256-2.
[3] 张叔人. 放疗联合免疫治疗肿瘤是今后重要的研究领域[J]. 实用肿瘤杂志, 2015, 30(6):491-495. DOI:10.13267/j.cnki.syzlzz.2015.06.023. Zhang SR. Radiotherapy combined with immunotherapy for tumor will be an important research field[J]. J Pract Oncol, 2015, 30(6):491-495.
[4] 高黎,徐国镇. 鼻咽癌[M]. 北京:北京大学医学出版社, 2007:49. Gao L, Xu GZ. Nasopharyngeal carcinoma[M]. Beijing:Peking University Medical Press, 2007:49.
[5] 黄少祥,樊体强. 塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J]. 国际放射医学核医学杂志, 2013, 37(3):150-152. DOI:10.3760/cma.j.issn.1673-4114.2013.03.006. Huang SX, Fan TQ. Radiosensitization on non-small cell lung cancer induced by celecoxib[J]. Inter J Radiat Med Nucl Med, 2013, 37(3):150-152.
[6] 陈晓艳, 张江虹, 邵春林. STAT3与辐射敏感相关性的研究进展[J]. 国际放射医学核医学杂志, 2016, 40(3):191-195. DOI:10. 3760/cma.j.issn.1673-4114.2016.03.007. Chen XY, Zhang JH, Shao CL. Research progresses of correlation between STAT3 and radiosensitivity[J]. Inter J Radiat Med Nucl Med, 2016, 40(3):191-195.
[7] 郑秀龙,金一尊,沈瑜. 肿瘤治疗增敏药[M]. 上海:上海科学技术文献出版社, 2002:12-14. Zheng XL, Jin YZ, Shen Y. Tumor therapy sensitizers[M]. Shanghai:Shanghai Science and Technical Literature Press, 2002:12-14.
[8] Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy[J]. Radiology, 1972, 105(1):135-142. DOI:10.1148/105.1.135.
[9] Oronsky B, Scicinski J, Ning S, et al. Rockets, radiosensitizers, and RRx-001:an origin story part I[J]. Discov Med, 2016, 21(115):173-180.
[10] Mercer WE. Checking on the cell cycle[J]. J Cell Biochem Suppl, 1998(S30-31):50-54. DOI:10.1002/(SICI)1097-4644(1998)72:30/31+3.3.CO;2-#?.
[11] Watanabe T, Ichikawa A, Saito H, et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma[J]. Leuk Lymphoma, 1996, 21(5/6):391-397.DOI:10.3109/10428199609093436.
[12] Vitturi DA, Sun CW, Harper VM, et al. Antioxidant functions for the hemoglobin β93 cysteine residue in erythrocytes and in the vascular compartment in vivo[J]. Free Radic Biol Med, 2013, 55(1):119-129. DOI:10.1016/j.freeradbiomed.2012.11.003.
[13] Scicinski J, Oronsky B, Ning S, et al. NO to cancer:The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001[J]. Redox Biol, 2015, 6(4):1-8. DOI:10.1016/j.redox.2015.07.002.
[14] Fens MH, Larkin SK, Oronsky B, et al. The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions[J/OL]. PLoS One, 2014, 9(7):e101626[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090171/pdf/pone.0101626.pdf.DOI:10.1371/journal.pone.0101626.
[15] Grubina R, Huang Z, Shiva S, et al. Concerted nitric oxide formationand release from the simultaneous reactions of nitrite with deoxy-and oxyhemoglobin[J]. J Biol Chem, 2007, 282(17):12916-12927. DOI:10.1074/jbc.M700546200.
[16] Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation[J]. Nat Med, 2003, 9(12):1498-1505. DOI:10.1038/nm954.
[17] Straessler NA, Cannizzo LF, Li P, et al. Methods of synthesizing and isolating N-(bromoacetyl)-3, 3-dinitroazetidine and a composition including the same:US, WO 2011/100090A1[P]. 2011-08-18.
[18] Ning S, Bednarski M, Oronsky B, et al. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials[J]. Cancer Res, 2012, 72(10):2600-2608. DOI:10.1158/0008-5472.CAN-11-2303.
[19] Ning S, Tian J, Marshall DJ, et al. Anti-alphav integrin monoclo-nal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats[J]. Cancer Res, 2010, 70(19):7591-7599. DOI:10.1158/0008-5472. CAN-10-1639.
[20] Scicinski J, Oronsky B, Cooper V, et al. Development of methods for the bioanalysis of RRx-001 and metabolites[J]. Bioanalysis, 2014, 6(7):947-956. DOI:10.4155/bio.13.331.
[21] Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer:a first-in-human, open-label, dose-escalation phase 1 study[J]. Lancet Oncol, 2015, 16(9):1133-1142. DOI:10.1016/S1470-2045(15)00089-3.
[22] Oronsky B, Paulmurugan R, Foygel K, et al. RRx-001:a systemi-cally non-toxic M2-to-M1 macrophage stimulating and prosensiti-zing agent in Phase Ⅱ clinical trials[J]. Expert Opin Investig Drugs, 2017, 26(1):109-119. DOI:10.1080/13543784.2017.1268600.
[23] Kim MM, Parmar H, Cao Y, et al. Whole brain radiotherapy and RRx-001:two partial responses in radioresistant melanoma brain metastases from a phase Ⅰ/Ⅱ clinical trial:a TITE-CRM phase Ⅰ/Ⅱ clinical trial[J]. Transl Oncol, 2016, 9(2):108-113. DOI:10.1016/j.tranon.2015.12.003.
[24] Yalcin O, Oronsky B, Carvallho LJ, et al. From METS to malaria:RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria[J]. Malar J, 2015, 14(1):218. DOI:10.1186/s12936-015-0720-5.
[25] Oronsky B, Scicinski J, Reid T, et al. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhi-bits glucose 6-phosphate dehydrogenase in human tumor cells[J]. Discov Med, 2016, 21(116):251-265.
[26] Cabrales P, Oronsky B, Scicinski J. Abstract 1420:RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydroge-nase[J]. Cancer Res, 2014, 74(19 Suppl):1420. DOI:10.1158/1538-7445. AM2014-1420.

相似文献/References:

[1]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[2]刘晓秋,周则卫,沈秀,等.放射增敏剂尼可胺对Wistar大鼠致畸作用的研究[J].国际放射医学核医学杂志,2013,37(2):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
　LIU Xiao-qiu,ZHOU Ze-wei,SHEN Xiu,et al.Study on teratogenicity of Nikean in Wistar rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
[3]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[4]李卫红,王浩,周晓靓,等.肿瘤放射治疗增敏剂研究新进展[J].国际放射医学核医学杂志,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
　LI Wei-hong,WANG Hao,ZHOU Xiao-liang,et al.Radiosensitizers development and the pathways[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
[5]刘晓秋,沈秀,王芹,等.尼可胺在大鼠体内的药代动力学研究[J].国际放射医学核医学杂志,2013,37(5):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
　LIU Xiao-qiu,SHEN Xiu,WANG Qin,et al.Study on pharmacokinetics of NiKeAn in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
[6]李玉,董丹,阎英.肿瘤辐射增敏机制研究进展[J].国际放射医学核医学杂志,2007,31(1):48.
　LI Yu,DONG Dan,Yah Ying.The development of radiosensitizer mechanisms[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):48.
[7]顾菲,刘晓秋.肿瘤辐射增敏的分子机制[J].国际放射医学核医学杂志,2006,30(5):298.
　GU Fei,LIU Xiao-qiu.The molecular mechanism of tumor radiosensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):298.
[8]秦阳华,韩玲.辐射诱导旁效应研究进展[J].国际放射医学核医学杂志,2004,28(5):234.
　QIN Yang-hua,HAN Ling.Progress of radiation-induced bystander effect[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(3):234.
[9]龚守良.一氧化氮与电离辐射[J].国际放射医学核医学杂志,2000,24(4):170.
　GONG Shou-liang.Nitric oxide and ionizing radiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):170.
[10]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]

备注/Memo

备注/Memo:
收稿日期:2017-02-20。
基金项目:中国医学科学院医学与健康科技创新工程资助（2016-12M-3-022）
通讯作者:李祎亮,Email:liyiliang75@163.com
更新日期/Last Update: 2017-06-28